港股異動｜康希諾生物升4.5% 重組帶狀皰疹疫苗於加拿大啟動I期臨牀試驗

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

港股異動｜康希諾生物升4.5% 重組帶狀皰疹疫苗於加拿大啟動I期臨牀試驗

格隆匯 11-09 09:46

康希諾生物(6185.HK)升4.5%，報29港元。康希諾公吿，公司的重組帶狀皰疹疫苗(腺病毒載體)近日於加拿大啟動I期臨牀試驗，並完成首例受試者入組。重組帶狀皰疹疫苗開展的I期臨牀試驗採取肌肉注射及吸入給藥方式，以評價其安全性及初步免疫原性。

康希諾生物(06185.HK)

Relevant Stocks

康希諾生物(06185.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

港股異動｜康希諾生物升4.5% 重組帶狀皰疹疫苗於加拿大啟動I期臨牀試驗

Services

About Us

Agreement Statement